NASDAQ:AGIO - Agios Pharmaceuticals, Inc.
$55.97
 $-0.37
-0.66%
4:00PM EDT
2019-04-18
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  AGIO     avg for
industry  
  avg for
sector  
42 stocks weight:  214. 86   0. 00   0. 00  
42 stocks rank:  1. 11 K 1. 43 K 1. 06 K
# analyst opinions:  8. 00   14. 48   14. 09  
mean recommendation:  2. 00   2. 09   2. 01  

quick ratio:  6. 37   5. 29   1. 92  
current ratio:  6. 56   5. 64   2. 40  

target price low:  75. 00   84. 50   115. 74  
target price avg:  86. 00   110. 73   137. 39  
target price high:  100. 00   136. 43   157. 80  
1-yr high:  99. 55   114. 11   138. 85  
last close:  55. 97   87. 56   116. 78  
50-day avg:  62. 31   95. 43   123. 53  
200-day avg:  66. 53   94. 13   121. 20  
1-yr low:  42. 73   72. 67   98. 41  
volume:  286. 06 K 2. 43 M 4. 85 M
50-day avg volume:  428. 73 K 2. 72 M 4. 97 M
200-day avg volume:  464. 35 K 2. 90 M 4. 58 M

1-day return:  -0. 66 % -0. 40 % 0. 07 %
this week return:  -8. 72 % -5. 72 % -4. 11 %
12-wk return:  7. 18 % 1. 78 % -0. 04 %
52-wk return:  -28. 01 % 10. 81 % 14. 09 %

enterprise value (EV):  3. 18 B 51. 19 B 117. 96 B
market cap:  3. 27 B 43. 00 B 104. 52 B
EBITDA:  -355. 31 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -8. 96   4. 34   13. 27  
enterprise/revenue (EV/R):  33. 72   68. 16   13. 68  
total revenue:  94. 39 M 10. 61 B 38. 24 B
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -346. 03 M 2. 20 B 4. 21 B

shares outstanding:  58. 40 M 570. 91 M 1. 24 B
shares:  51. 09 M 571. 02 M 1. 23 B
shares short:  8. 27 M 9. 93 M 16. 79 M
shares short prior month:  7. 33 M 9. 96 M 16. 58 M
short ratio:  16. 66   5. 31   3. 30  
short % of float:  28. 46 % 5. 81 % 2. 61 %
total cash/share:  10. 02   11. 13   9. 30  
total cash:  585. 30 M 6. 70 B 7. 10 B
free cash flow:  -161. 60 M 3. 58 B 4. 74 B
operating cash flow:  -304. 42 M 4. 14 B 6. 32 B

book value:  11. 81   12. 76   26. 84  
price/book:  4. 74   3. 08   -1. 74  
gross profits:  -248. 33 M 8. 03 B 34. 77 B
operating margins:  -384. 04 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  -263. 10 % 37. 02 % 55. 68 %

1-yr max volatility:  -13. 66 % --- ---
1-yr mean volatility:  -0. 13 % 0. 03 % 0. 04 %

1-yr EPS:  -6. 03   2. 39   4. 08  
forward EPS:  -6. 21   3. 97   7. 14  
P/E:  -9. 29   13. 59   22. 83  
forward P/E:  -9. 87   -20. 05   14. 49  
PE/G:  -0. 05   -1. 46   1. 68  
growth:  206. 30 % 126. 81 % 29. 29 %
earnings high:  -1. 66   1. 02   1. 63  
earnings avg:  -1. 75   0. 76   1. 51  
earnings low:  -2. 01   0. 47   1. 39  
revenue high:  26. 88 M 2. 68 B 10. 71 B
revenue avg:  22. 69 M 2. 59 B 10. 49 B
revenue low:  14. 39 M 2. 49 B 10. 25 B
return on assets:  -30. 76 % -2. 80 % 5. 29 %
return on equity:  -65. 10 % -18. 52 % 7. 38 %
revenue growth:  206. 30 % 92. 55 % 19. 15 %
revenue/share:  1. 64   13. 27   55. 24  

beta (1yr vs S&P500):  1. 65   1. 24   0. 93  
sharpe (1yr):  -0. 63   0. 29   0. 60  

held % insiders:  12. 93 % 6. 38 % 3. 38 %
held % institutions:  102. 16 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-18 : AGIO
.    + 1.455 =         1.455 :: INITIAL WEIGHT
.   + 25.864 =         27.32 :: inverse volume-to-price addition
.    + 46.92 =        74.239 :: spline projection addition
.    x 1.735 =       128.819 :: 13 weeks' performance factor
.     x 0.78 =       100.506 :: one-year gains+dividend factor
.    x 1.432 =       143.927 :: industry recommendation factor
.    x 2.206 =       317.497 :: symbol recommendation factor
.    x 1.495 =       474.541 :: EV/R factor
.    x 0.997 =       473.082 :: return on assets factor
.    x 0.993 =       470.002 :: return on equity factor
.    x 2.326 =      1093.287 :: revenue growth factor
.    x 2.836 =      3100.406 :: current ratio factor
.    x 1.089 =      3376.718 :: quick ratio factor
.     x 1.03 =      3476.584 :: short ratio factor
.    x 2.047 =       7117.93 :: price-to-book factor
.    x 1.996 =     14210.523 :: P/E weight
.    x 2.171 =     30849.868 :: PE/G factor
.    x 1.385 =     42716.532 :: beta factor
.    x 0.634 =     27086.226 :: sharpe factor
.    x 1.614 =     43728.726 :: target low factor
.    x 1.244 =     54405.636 :: target mean factor
.    x 1.089 =     59231.117 :: target high factor
.    x 1.312 =     77690.398 :: industry 2-weeks return factor
.    x 0.953 =     74050.577 :: "drift" penalty 2 days ago
.    x 0.921 =     68165.393 :: "drift" penalty 4 days ago
.    x 0.996 =     67890.264 :: overall "drift" factor
.    x 0.999 =     67851.935 :: largest single-day jump factor
.      x 1.0 =     67840.998 :: factor hist industry gain for week 15
.   cubeRoot =        40.785 :: reduced to standardize
.  + 174.074 =       214.859 :: add/subtract for performance
.                    214.859 :: FINAL WEIGHT for NASDAQ:AGIO


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org